Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 18 |
| Active Pipeline (Recruiting Now) | 1 (1) |
| Completed vs Stopped Early | 8 / 9 (50.0%) |
| Median Closed Actual Enrollment | 66 participants |
| Physical Hospital Site Disclosure | 99.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UZ Leuven | Leuven, Flemish Brabant | 6 |
| Tufts Medical Center | Boston, MA | 3 |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03733444 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together Wit | Phase III | TERMINATED |
| NCT03711162 | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With St | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Lakefront Biotherapeutics NV Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.